The body's own repair peptide
A 15-residue peptide derived from gastric juice, used for tissue and gut repair.
Educational content. This page describes BPC-157 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Modulates the nitric oxide system and reduces inflammatory markers including IL-6 and TNF-alpha throughout the body.[5]
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (GEPPPGKPADDAGLV, MW 1419). It is derived from a protective protein naturally found in human gastric juice, which contributes to the stomach's remarkable ability to heal itself.
Originally characterized in the late 1990s, BPC-157 has been the subject of over 200 published studies investigating its regenerative properties across multiple body systems. Its stability in gastric acid (remaining active for more than 24 hours) sets it apart from most peptides and enables both oral and injectable administration.
BPC-157 exerts its healing effects through multiple interconnected pathways. It promotes angiogenesis (new blood vessel formation) comparable to established growth factors like VEGF and FGF, which is critical for delivering nutrients and oxygen to injured tissues.
At the molecular level, BPC-157 activates the FAK-paxillin signaling cascade, promoting cell migration and survival, both essential processes for tissue repair. It also modulates the nitric oxide (NO) system by influencing eNOS gene expression, which supports endothelial protection and vascular integrity.
Additionally, BPC-157 stimulates early growth response gene-1 (Egr-1) and its repressor NAB2, triggering a coordinated cascade of cytokine and growth factor production that orchestrates the healing response.
The body's own repair peptide
BPC-157 activates multiple regenerative pathways simultaneously, from FAK-paxillin signaling for cell repair to NO-system modulation for vascular protection, creating a coordinated healing response across tissues.
Key studies supporting the therapeutic use of this peptide.
BPC-157 significantly promoted granulation tissue formation, angiogenesis, and collagen production in skin wounds, colon anastomoses, and sponge implant models. Effects were achieved via multiple routes including intragastric administration.
Seiwerth S, Sikiric P, et al. — Journal of Physiology Paris, 91(3-5):173-178 (1997) · PubMed
Demonstrated dose-dependent activation of FAK-paxillin signaling pathway, accelerating tendon fibroblast outgrowth and cell survival under oxidative stress. Notably conducted by an independent group in Taiwan.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH — Journal of Applied Physiology, 110(3):774-780 (2011) · PubMed
Independent critical review from Loughborough University found consistently positive healing effects for tendon, ligament, and muscle tissue with few reported adverse reactions across the literature.
Gwyer D, Wragg NM, Wilson SL — Cell and Tissue Research, 377(2):153-159 (2019) · PubMed
BPC-157 was safe and well-tolerated in Phase II clinical trials for inflammatory bowel disease. No toxicity was reported. These represent the most advanced human clinical data available.
Sikiric P, Seiwerth S, Brcic L, et al. — Inflammopharmacology, 14(5-6):214-221 (2006) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection
Oral
Subcutaneous Injection: Most common route for musculoskeletal injuries. Inject near the site of injury when possible.
Oral: Preferred for gut-related conditions. BPC-157 is uniquely stable in gastric acid (>24 hours).
Dosing should always be determined by a licensed provider based on your specific condition, body weight, and treatment goals.
Typical protocols involve 4–8 weeks on followed by 2–4 weeks off. Many patients report noticeable improvements within the first 1–2 weeks.
BPC-157 is commonly combined with Thymosin Beta-4 (TB-500) for enhanced healing effects.
In preclinical studies, the LD1 (lethal dose for 1% of subjects) was never achieved, suggesting a very wide safety margin. No organ toxicity has been reported in any published study.
In human Phase II clinical trials for inflammatory bowel disease, BPC-157 was well-tolerated with no reported toxicity.
Long-term human safety data beyond clinical trial periods remains limited. BPC-157 is not FDA-approved as a drug.
See how BPC-157 compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Uniquely stable in gastric acid; broad multi-system healing with human IBD trial data |
| GHK-Cu | Anti-Aging & Recovery | Topical, Injection | 8–12 weeks | Only peptide demonstrated to modulate ~31% of human genes, epigenetically resetting cellular function toward a younger phenotype |
| CJC-1295 | Anti-Aging & Recovery | Injection (weekly or daily) | 8–12 weeks | Only GHRH analog with covalent albumin-binding mechanism extending half-life to 6-8 days, allowing once-weekly dosing |
| Thymosin Beta-4 | Recovery & Healing | Injection | 6–12 weeks | Only peptide demonstrated to activate dormant cardiac progenitor cells for heart tissue regeneration |
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical | 4 to 8 weeks | Smallest known anti-inflammatory peptide that directly blocks NF-kB nuclear import without melanocortin receptor binding, cAMP elevation, or pigmentation effects |
Current FDA classification and compounding eligibility.
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in 503A Category 2 since September 2023. FDA identified immunogenicity risks for injectable routes and complexities with peptide-related impurities. The nominator withdrew the nomination in September 2024, but FDA is continuing evaluation. Not eligible for compounding under the interim policy.
Placed in 503A Category 2 with significant safety risks identified for compounding
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into BPC-157? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A stabilized GHRH analog designed to extend the half-life of natural growth hormone pulses.
Widely compounded before 2023; currently flagged by FDA for aggregation and immunogenicity concerns.
A 43-residue peptide involved in actin dynamics, angiogenesis, and tissue repair.
Marketed as TB-500 in fragment form; angiogenesis mechanism raised tumor-growth concerns during FDA review.